Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
boomshiva
boomshiva Apr. 24 at 9:35 PM
$MDNAF The heck? History shows that it'll give it all back on Monday.
0 · Reply
Gobblin
Gobblin Apr. 24 at 9:09 PM
$MDNAF - nice bump up today but still in the tank. A long way to go to get back to most recent high
0 · Reply
bobwut12
bobwut12 Apr. 23 at 10:17 PM
$MDNAF @Spartrap seemingly chose the perfect time to dip lol - the stock has tanked since. As a super long bagholder from the pre-NASDAQ delisting days, the price action really hurts to watch. Dr. Merchant really really needs to get that funding, I don't want us to get into resorting to infinite dilution like $BCTX does.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Apr. 23 at 7:56 PM
$MDNAF $XLO No anchoring in the TME and IL2 alpha???? If the cancer doesn’t kill ya that treatment probably will. No thanks I’ll stick with MDNA113
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 23 at 6:46 PM
$MDNAF $XLO I think there may a use for both approaches
0 · Reply
Gobblin
Gobblin Apr. 22 at 10:28 PM
$MDNAF the market is not reacting to shit
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 4:48 PM
$MDNAF Lets if they can pull a decent PIPE. All decent small biotechs seem to be getting one
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 4:40 PM
$MDNAF I hadnt realized they had a masked PDL1-IL2 too $XLO
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Apr. 21 at 2:54 PM
$MDNAF The only thing that matters right now is money. We have none. To get what they need at this share price the dilution for us longs will be horrific !
0 · Reply
Gobblin
Gobblin Apr. 21 at 2:32 PM
$MDNAF - according to chat on headline alone What matters in this announcement 1. “anti-PD-1 x IL-2 bifunctional superkine” This is the core of the story. MDNA113 is trying to solve a known problem: * PD-1 drugs (Keytruda, Opdivo) work but many patients don’t respond * IL-2 is powerful but historically too toxic Combining them into a tumor-targeted, conditionally activated molecule is meant to: * Activate immune response only in the tumor microenvironment * Avoid systemic IL-2 toxicity (the graveyard of prior IL-2 drugs) If that targeting actually holds up, that’s a big deal.
0 · Reply
Latest News on MDNAF
No data available.
boomshiva
boomshiva Apr. 24 at 9:35 PM
$MDNAF The heck? History shows that it'll give it all back on Monday.
0 · Reply
Gobblin
Gobblin Apr. 24 at 9:09 PM
$MDNAF - nice bump up today but still in the tank. A long way to go to get back to most recent high
0 · Reply
bobwut12
bobwut12 Apr. 23 at 10:17 PM
$MDNAF @Spartrap seemingly chose the perfect time to dip lol - the stock has tanked since. As a super long bagholder from the pre-NASDAQ delisting days, the price action really hurts to watch. Dr. Merchant really really needs to get that funding, I don't want us to get into resorting to infinite dilution like $BCTX does.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Apr. 23 at 7:56 PM
$MDNAF $XLO No anchoring in the TME and IL2 alpha???? If the cancer doesn’t kill ya that treatment probably will. No thanks I’ll stick with MDNA113
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 23 at 6:46 PM
$MDNAF $XLO I think there may a use for both approaches
0 · Reply
Gobblin
Gobblin Apr. 22 at 10:28 PM
$MDNAF the market is not reacting to shit
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 4:48 PM
$MDNAF Lets if they can pull a decent PIPE. All decent small biotechs seem to be getting one
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 4:40 PM
$MDNAF I hadnt realized they had a masked PDL1-IL2 too $XLO
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Apr. 21 at 2:54 PM
$MDNAF The only thing that matters right now is money. We have none. To get what they need at this share price the dilution for us longs will be horrific !
0 · Reply
Gobblin
Gobblin Apr. 21 at 2:32 PM
$MDNAF - according to chat on headline alone What matters in this announcement 1. “anti-PD-1 x IL-2 bifunctional superkine” This is the core of the story. MDNA113 is trying to solve a known problem: * PD-1 drugs (Keytruda, Opdivo) work but many patients don’t respond * IL-2 is powerful but historically too toxic Combining them into a tumor-targeted, conditionally activated molecule is meant to: * Activate immune response only in the tumor microenvironment * Avoid systemic IL-2 toxicity (the graveyard of prior IL-2 drugs) If that targeting actually holds up, that’s a big deal.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Apr. 21 at 11:45 AM
$MDNAF Let’s hopes this get us some traction! https://ir.medicenna.com/news-releases/news-release-details/medicenna-presents-positive-data-demonstrating-superior-safety
0 · Reply
Rvin
Rvin Apr. 21 at 11:45 AM
$MDNAF https://ir.medicenna.com/news-releases/news-release-details/medicenna-presents-positive-data-demonstrating-superior-safety
0 · Reply
Biosectors
Biosectors Apr. 17 at 4:06 PM
$MDNAF Tuesday’s 113 data and reactions from analyst, market and corporate update will decide medicennas forward path. Next 2 quarters will make or break with the new cmo , 2 M & A experts and RA capital behind them to support. Long and praying it’s about time to get our dues for patience and investment. I am highly optimistic with recent updates and onboarding of experts scientists to business deal makers.
1 · Reply
Lytnup
Lytnup Apr. 17 at 2:32 PM
$MDNAF New website is live. https://www.medicenna.com I remain cautiously optimistic that next week’s presentations, coupled hopefully with input & exposure from the new CMO, will finally break through the partnership barriers.
1 · Reply
_Osmium
_Osmium Apr. 16 at 5:45 PM
$MDNAF Another new 52 week low. Pet peeve of mine - TWO months ago, two new directors, Sutin and Georgakis were hired and Medicenna still hasn't bothered to update their website. https://www.medicenna.com/about-medicenna/board-of-directors/
3 · Reply
Biosectors
Biosectors Apr. 16 at 4:30 PM
$MDNAF New fractional CMO on board an Ex-Merck lead of keytruda and also at GSK give some credibility and hope for the upcoming 113 data read out on Tuesday at 2 conferences followed by a corporate update. Hoping this read out and update will help us all in taking Medicenna closer to a buy out in this quarter. It looks like they are very bullish on 113 data that most likely meets and solves the IL2 issues where big boys spent billions and failed. Good luck all
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Apr. 16 at 1:12 PM
$MDNAF …. It’s interesting that Fahar is leaving the much touted AACR to be present at Bloom Burton on the 22nd….PLEASE BE A FUNDING ANNOUNCEMENT
2 · Reply
boomshiva
boomshiva Apr. 15 at 7:22 PM
$MDNAF And again.
1 · Reply
boomshiva
boomshiva Apr. 14 at 1:39 PM
$MDNAF SP is always, always a party-pooper.
0 · Reply
TraderBuckNKY
TraderBuckNKY Apr. 14 at 1:29 PM
$MDNAF ORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant , President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2026 Bloom Burton & Co. Healthcare Investor Conference , taking place in Toronto on April 21-22, 2026 . During this investor presentation, the Company will provide a corporate update as well as latest MDNA113 preclinical data from the 2026 Annual Meeting of the American Association for Cancer Research (AACR). More details are as follows: Date: Tuesday, April 21, 2026 Time: 3:00 p.m. Eastern Time Location: Metro Toronto
0 · Reply
Gobblin
Gobblin Apr. 13 at 6:40 PM
$MDNAF from X Like the words “compelling new preclinical & non- human primates data”. Combine this with hiring of Dr.Ibrahim I am getting a good vibe about Medicenna!!
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Apr. 10 at 6:31 PM
$MDNAF Abstract to be presented on the 21st April https://aacrjournals.org/cancerres/article/86/7_Supplement/4342/780995/Abstract-4342-MDNA113-is-a-masked-conditionally
3 · Reply